News - Markets & Marketing, Eisai

Filter

Current filters:

Markets & MarketingEisai

Popular Filters

1 to 25 of 37 results

Eisai’s Fycompa debuts in France following reimbursement agreement

21-05-2014

Japanese pharma company Eisai has launched its Fycompa (perampanel), the first in an entirely new class…

EisaiFranceFycompaMarkets & MarketingNeurologicalPharmaceuticalPricing

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA

02-01-2014

The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Eisai ties up with Newbridge to market Halaven in Middle East

Eisai ties up with Newbridge to market Halaven in Middle East

18-11-2013

Japanese drug major Eisai says that its breast cancer drug Halaven (eribulin) will be marketed in selected…

EisaiHalavenMarkets & MarketingNewBridge PharmaceuticalsOncologyPharmaceuticalRest of the World

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December

15-10-2013

Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Eisai's launch plan for obesity drug Belviq in USA enters consumer phase

16-09-2013

The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Eisai's new Belgium operation to help firm's globalization aims

16-09-2013

Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of Japanese drug major Eisai…

EisaiEuropeHalavenInovelonMarkets & MarketingOncologyPharmaceuticalRare diseases

Breast cancer drug Halaven now available in Russia

12-09-2013

Japanese drug major Eisai (TYO: 4523) said this morning (September 12) that Halaven (eribulin) is now…

EisaiEuropeHalavenMarkets & MarketingOncologyPharmaceutical

Eisai gains WHO prequalification for DEC; launches high-dose Aricept in Korea

27-08-2013

Japanese drug major Eisai (TYO: 4523) has received prequalification from the World Health Organization…

AriceptAsia-PacificdiethylcarbamazineEisaiMarkets & MarketingNeurologicalPharmaceuticalRegulationTropical diseases

Eisai temporarily suspend Fycompa in Germany, following negative G-BA decision

25-06-2013

Japanese drug major Eisai (TYO: 4523) said today (June 25) that, "with regret," it will suspend temporarily…

EisaiEuropeFycompaMarkets & MarketingNeurologicalPharmaceuticalPricingRegulation

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Arena/Eisai's Belviq at last to launch in the USA

07-06-2013

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that its long-awaited weight loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments

03-06-2013

Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Eisai joins trend to enter Russian pharma market, with Halaven launch

26-03-2013

Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced…

EisaiEuropeExaliefFycompaHalavenInovelonMarkets & MarketingNeurologicalOncologyPharmaceuticalZonegran

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

Treatment landscape for thyroid carcinoma will change dramatically through 2021; report

05-02-2013

Through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the USA and Europe…

BayerdabrafenibEisaiEuropeGlaxoSmithKlinelenvatinibMarkets & MarketingNexavarNorth AmericaOncologyOXiGENEPharmaceuticalRochetrametinibZelborafZybrestat

Eisai expands in South Africa, filing for approval of Halaven and Fycompa

30-01-2013

Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Insights on the US Alzheimer's disease market

03-12-2012

The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

European Alzheimer's drug market to grow to $4.78 billion by 2019, says F&S

25-11-2012

The patent expiry of all four existing European Medicines Agency-approved drugs for Alzheimer's disease…

AriceptEbixaEisaiEuropeExelon PatchLundbeckMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalResearch

1 to 25 of 37 results

Back to top